Printer Friendly

Recent developments in treatment of latent tuberculosis infection.

Introduction

It has been estimated by the World Health Organization (WHO) that more than one third of the entire world's population, or approximately 2 billion persons are infected and can be considered carriers of TB. From this vast pool of persons with latent TB infection (LTBI) approximately 200 million will tuberculosis prevention--tuberculosis treatment develop active TB during their lifetime (1). More than 80 per cent of these will be contagious and transmit TB infection to others, perpetuating the cycle of TB and resulting in continued morbidity and mortality from TB for generations to come (2). The impact of TB is even greater than these numbers may suggest, as 75 per cent of individuals with TB are within the economically productive age group of 15-54 yr (2), and TB disproportionately affects low and middle income countries, as 95 per cent of all cases and 99 per cent of all deaths occur in these countries (2).

Two approaches can be taken to reduce the burden of TB over the long term. One approach requires early and rapid diagnosis of all persons with active TB with institution of effective therapy to render them non contagious. This will reduce transmission, reducing the number of carriers, who will later develop active TB. However, WHO has estimated that less than 50 per cent of all cases globally are currently diagnosed and treated (1). Since each person with undiagnosed and untreated active TB will survive an average of 2 yr, it has been estimated that they will infect 20 others (2). An additional problem is that most patients in high incidence settings are diagnosed by direct smear microscopy of unconcentrated sputum specimens (3), which only detects patients with advanced disease. Hence, significant transmission can occur prior to diagnosis (2).

An alternate approach is to detect persons while they still have LTBI and treat them to prevent the later development of disease. This approach dates back to the 1950s. Soon after isoniazid (INH) was introduced as an effective agent to treat disease, clinicians noted that INH monotherapy effectively prevented development of disease in children with primary TB (4). Following this clinical observation, more than 20 randomized trials, involving more than 100,000 participants, were conducted in more than a dozen countries (5). These studies demonstrated that INH taken for at least 6 months in persons with LTBI reduced subsequent TB incidence by 25 to 92 per cent. The differences in effectiveness found in different studies were largely explained by differences in treatment completion (5).

However, INH treatment of LTBI is problematic for several reasons. The lengthy duration of treatment reduces patient compliance (6-8), while the potential occurrence of serious adverse events such as hepatitis, further discourages patients' and providers' acceptance of this therapy (9,10). As a result there has been considerable interest and many evaluations of alternative shorter regimens. This work continues even today.

The objectives of the present article are to (i) review the evidence from systematic reviews and recent trials of efficacy, completion, and adverse effects of several commonly used regimens for treatment of LTBI; (ii) review risk-benefit and other considerations for treatment of LTBI in high income, as well as low and middle income countries; and (iii) review the indications for tuberculin testing (or use of other methods of diagnosis of LTBI) prior to starting LTBI treatment.

Regimens for treatment of LTBI

6 Months INH (6INH)

Numerous trials have evaluated different durations of INH (11). However, only one clinical trial has directly compared regimens of different durations of INH. The International Unit Against Tuberculosis (IUAT) trial, conducted in Eastern Europe, randomized approximately 28,000 individuals with positive tuberculin skin tests (TST) and fibronodular changes on chest X-ray (12). Approximately 7,000 participants each were randomized to placebo, 3, 6 or 12 months of INH (Table I). Compliance was assessed with monthly pill counts. Compared to participants who took placebo, participants who completed 3 months INH had 31 per cent reduction in TB; this effect waned over the 5 years of follow up. Participants who completed 6 months INH had 69 per cent reduction of active TB, while subjects who completed 12 months INH (12INH) had 93 per cent reduction in TB. The efficacy of 6INH and 12INH waned during the 5 yr of follow up but always remained significantly better than placebo (12). However, completion of the 12 month regimen was much less than the 6 month regimen.

Based on these results, and assuming that under programme conditions completion of longer regimens would be equally poor, if not worse, many authoritative agencies have recommended 6INH as an acceptable alternative to 12INH (13,14). Snider and colleagues (15) estimated that 6INH would be more cost-effective than 12INH. This reflects the fact that the majority of costs of LTBI therapy is related to the initial screening, subsequent medical evaluation and start of therapy (16). However, it is important to remember that in patients who take therapy properly, 12INH is significantly and substantially more efficacious than 6INH.

9 Months INH (9INH)

Concerns regarding the relatively low efficacy of 6INH, and equally serious concerns regarding the poor completion of 12INH resulted in recommendations for 9 months INH by the American Thoracic Society in 2000 (13). This recommendation was based almost entirely upon a re-analysis by Dr George Comstock of data from several INH trials among Alaskan Inuit populations (17). This re-analysis demonstrated that the optimal duration of INH was 9 months, with estimated efficacy of 90 per cent and no significant gain with extension to 12 months. Hence, 9INH was recommended as the standard of care by the American Thoracic Society in 2000 (13), and other authorities followed suit soon after (14).

Completion of 9INH under programme conditions is poor. Many programmes report less than 50 per cent completion although a few programmes report much higher completion rates (18,19). These programmes emphasize initial intensive patient education, with subsequent close follow up, and patient support; they demonstrate that many patients can be motivated to complete 9 months therapy.

However, INH has the major disadvantage of potential serious adverse events. Of particular concern is hepatotoxicity, as this is difficult to detect, and can be fatal. Interestingly in the randomized trials conducted up to 1970 this problem had not been noted (20). Hence when INH was recommended by the American Thoracic

Society (ATS) in 1971, the potential for adverse effects was considered minimal, and this treatment was strongly recommended for TST reactors of all ages (21). With the ensuing much greater use, serious hepatotoxicity causing deaths was described (22). Subsequent surveillance studies confirmed that hepatotoxicity was quite common in patients taking INH, and could be severe, with up to 1 per cent mortality in older patients (23). Subsequently INH related mortality has declined over the last 30 yr (24,25) presumably--related to better selection of patients for therapy and closer follow up.

2 Months rifampin--pyrazinamide (2RZ)

Studies of latent TB infection in a mouse model revealed that 2 months of treatment with a combination of rifampin and pyrazinamide (PZA) resulted in complete clearance of TB bacilli-a bacteriologic effect comparable to that achieved with 6 months INH in the same mouse model. Following publication of these results in 1989 (26), several randomized trials were conducted to compare 6 to 12 months INH with 2RZ in HIV infected patients (27). These trials demonstrated equivalent efficacy; however, since most compared 2RZ to 6INH this would indicate that efficacy of 2RZ was likely less than the ideal achieved with 9INH. Serious adverse events were not more frequent with 2RZ than with INH in these trials. However, completion of 2RZ was not significantly better than completion of 6INH in several of these trials, despite the shorter duration (27). In retrospect, this may have been a harbinger of events to come.

In 2000, based on these promising trial results, the American Thoracic Society recommended use of 2RZ (13). This was a strong recommendation for use in HIV infected persons, and a conditional (or weak) recommendation for non-HIV infected persons. Publication of these recommendations was quickly followed by rapid, enthusiastic and widespread use of 2RZ. In turn this was quickly followed by reports of serious hepatotoxicity and death (28). Subsequent trials in non HIV infected individuals revealed very high rates of grade 3 to 4 hepatotoxicity, which sometimes occurred at the end or even after completion of therapy (27). As a result recommendations were revised that 2RZ should be used with caution in HIV infected and extreme caution in non HIV infected (29).

Our current practice is to consider use of this regimen in HIV infected individuals in situations where close supervision and monitoring is possible and longer therapy LTBI regimens may be impractical. We do not recommend this regimen in non-HIV infected persons.

4 Months rifampin (4RIF)

An overlooked finding in the same study of treatment of latent LTBI in mice was that rifampin alone for 2 months was equally efficacious as 2RZ, or 2 months of rifampin plus-INH (26). Complete bacteriologic clearing had occurred in all TB infected mice by the end of two months mono-RIF therapy. Unfortunately, despite this very promising evidence, only one randomized trial has evaluated a regimen of rifampin alone. In this trial, older men living in Hong Kong, who had pulmonary silicosis with a positive TST were randomized to placebo, 6INH, 3 months INH plus Rifampin, or 3 months Rifampin alone (30). During five years of follow up, 27 per cent of those randomized to placebo developed active TB, compared to 16, 13, and 10 per cent for the three regimens respectively. The estimated effectiveness of 3 months rifampin was approximately 65 per cent; this was better than the other regimens although the differences between active regimens was not significant, and all were significantly better than placebo (30). To date, there are no other published trial evaluating mono-RIF therapy. However, a large scale trial comparing the effectiveness and efficacy of 4RIF and 9INH is ongoing.

Several studies have reported that completion rates with 4RIF are substantially and significantly better than with 9INH (31-34). In addition, rates of serious adverse events with 4RIF are very low, particularly rates of hepatotoxicity (31). In a recently published randomized trial rates of grade 3 to 4 adverse events were significantly lower with 4RIF than 9INH. Grade 3-4 hepatotoxicity occurred in 4 per cent of patients taking 9INH compared to less than 1 per cent in those taking 4RIF (34). The earlier results in the Hong Kong silicosis trial suggest that 4RIF should have efficacy of at least 65 per cent (30)-equivalent to the documented efficacy of 6INH.

In summary, 4RIF appears to be well tolerated, has excellent completion and a very good safety record. However, 4RIF cannot be recommended for routine use until the results of the efficacy trial are available.

3 to 4 Months of INH and RIF (3-4INH-RIF)

The animal study described earlier suggested that INH and RIF for 2 months was effective in the mouse model. Uncontrolled trials in paediatric populations have suggested that this regimen should be adequate (35).

A series of randomized trials (36), have demonstrated that the efficacy of 3-4INH-RIF is equivalent to that of 6INH (4 studies) or 9INH (1 study) although adverse events are significantly more frequent (37). This latter finding is not that surprising, since the majority of hepatotoxic adverse events with INH occur in the first 2-3 months (34,38). Therefore adding INH to rifampin for 3 or 4 months will inevitably increase the risk of adverse events. However, the benefits of adding the INH to RIF are unclear. In theory, therapy with two agents will provide a margin of safety if the person has minimal active TB rather than true latent TB infection. There is no evidence of improved efficacy compared to RIF alone, and to justify LTBI therapy on the basis of potential misdiagnosis of active TB as latent TB seems a fairly weak rationale for this regimen.

New regimens

A trial comparing 9INH with 3 months of once weekly directly observed INH combined with rifapentine (3INH-RPT) has just been completed. Rifapentine is a rifamycin with half life that is 5 times longer than rifampin-allowing once weekly therapy. More than 8,000 participants were randomized. Completion of 3INH-RPT was 84 per cent, compared to 71 per cent completing 9INH. Efficacy and safety data are still being analyzed, but results are expected soon. If these are acceptable, this may be an excellent alternative regimen. However, the requirements for directly observed preventive therapy may make this impractical in some settings.

In addition, the experience with INH in 1970, and the 2RZ regimen in 2000 should provide a cautionary note for implementation of this new regimen. For both of these regimens the potential for serious and even fatal adverse events was not detected in multiple randomized trials. The serious hepatotoxicity of both regimens was only recognized after these had been recommended and implemented widely in routine practice. Rifapentine is a relatively new and untested drug. Hence this drug may cause unexpected adverse events that were not detected in the randomized trial. Given the long half life of this drug the adverse events may progress even after treatment is stopped, resulting in more serious sequelae. Hence, introduction of this new regimen should be accompanied by careful monitoring and evaluation of adverse events.

Drug-resistant LTBI

Treatment of close contacts of drug resistant active cases is difficult and yet is an increasingly common clinical problem. For contacts of INH resistant index cases, INH will be ineffective (39), so 4RIF is recommended (13,14). Contacts of index cases with MDR TB are recommended to receive 6 months of PZA and a quinolone (13). However, two observational studies have reported very high rates of toxicity and extremely poor completion due to intolerance (40,41). In both series no patients actually completed the proposed 6 month course of therapy. Based on this and our own clinical experience which was similar, our current practice is to give moxifloxacin or levofloxacin alone for 6 months. The rationale for this monotherapy is the published evidence that moxifloxacin can replace INH in treatment of active TB (42).

Consideration for use in different settings

Over the past 30-40 yr treatment of LTBI has been a major priority for TB control programmes in many high income countries such as Canada, U.S.A., Australia or Saudi Arabia. However, LTBI diagnosis and treatment has been a low priority for TB control programmes in most low and middle income countries (LMIC). This reflects the cost and resources required for effective and safe treatment of LTBI, given the need for close follow up and monitoring to detect serious adverse events and to encourage and monitor compliance with therapy. Until an LTBI regimen is found that is perfectly safe and very easy to take, these resource requirements will be present. Medication costs are low, but micro costing studies have shown that medications account for less than 10 per cent of total resources used (16,43). Nevertheless therapy of individuals with LTBI and important risk factors for reactivation such as HIV co-infection, or close contacts is warranted in all settings as this therapy provides significant individual benefits, and is much more cost-effective.

In high income settings, the costs are not as determinant of LTBI therapy as risk-benefit considerations. After realization that serious adverse events and even deaths could occur with INH, several investigators performed decision analyses to estimate the risks and benefits of INH therapy. As shown in Table II, the majority of these studies examined the risks and benefits of treatment with INH in healthy individuals with a positive tuberculin skin test but no other risk factors. In these individuals the benefits of INH therapy are low because the life-time risk of development of active TB is low. Therefore, the benefits barely exceeded the risks. And, because of slightly different assumptions made by the different investigators, INH therapy was found to result in small net gains or losses of life expectancy. However, the absolute differences in findings between these studies were very small (44-48). Despite this, the authors concluded, often very strongly, that 9INH was good, or was bad. These apparently contradictory findings resulted in greater confusion about benefits of, and indications for, treatment of LTBI. These may have contributed to the chronic under use of LTBI treatment. Risk-benefit analyses of INH therapy in HIV infected individuals (49,50) or other high risk groups (19) have estimated much greater, and consistent benefits. These analyses support current recommendations to test and treat LTBI only in individuals with high risk of reactivation to disease, if infected (13,14).

There are many factors that increase the risk of re-activation. In view of this complexity, a web based algorithm has been developed which may provide some assistance in estimating that risk (51). This algorithm, (available at www.tstin3d.com) incorporates information on age, TST or interferon gamma release assay (IGRA) results, country of birth, ethnic origin and clinical risk factors including chest radiographic findings. This information is entered and the algorithm calculates the likelihood of true latent infection, as well as the annual and cumulative life time risk of development of active TB.

One important consideration for any programme for screening and treatment for LTBI is its potential public health impact. This is of particular interest in LMIC given the resource implications of initiating such a programme. As seen in Table III, several studies have described the impact of LTBI screening and treatment programmes in many different settings (16,43,52,57). In all these studies, the public health impact was very low. This is because patients did not participate in initial screening or failed to come for reading of tuberculin results, or did not report for medical evaluation of positive tests. In addition physicians were non-compliant with recommendations to prescribe treatment, and then patients refused to start LTBI therapy, or they were non-compliant if they did start. As a result, in all these studies fewer than 40 per cent of patients who could have benefited from LTBI therapy actually did so; in some studies as few as 10 per cent with presumed LTBI derived any benefit. If LTBI screening and treatment is being considered, then a great deal of attention must be paid to ensure that every stage of the programme is well organized, in order to enhance the public health benefit of this approach.

Is testing for latent TB infection required before latent TB treatment?

A common clinical question is whether a TST or an IGRA is needed prior to giving LTBI therapy. This is particularly important in LMIC that are initiating LTBI therapy because tuberculin testing is not commonly performed. In some LMIC the tuberculin material itself (i.e., the PPD) is not available. In addition, WHO has recommended that LTBI therapy can be given without performing a TST (58).

This question has been addressed in several randomized trials and in one systematic review. In these trials INH therapy was compared to placebo in HIV infected patients who had initial TST, but were randomized to active therapy or placebo regardless of TST results (59-64). There is convincing evidence, (Table IV) that a positive TST predicts benefit from INH therapy. INH therapy is of minimal and non-significant benefit in HIV infected persons who are initially TST negative. Based on the systematic review of the earlier trials in HIV infected INH provides 60 per cent protection against disease in TST positive, but only 16 per cent benefit in TST negative persons (65).

A trial just completed in Botswana confirmed these findings. In this trial HIV infected patients were randomized to 6 or 36 months of INH. In those who were initially TST positive, 36 months INH resulted in 92 per cent reduction in TB disease relative to those who received only 6 months INH. However, participants who were initially TST negative had only a 14 per cent reduction in TB disease with 36 months INH, compared to 6INH-a reduction that was not statistically significant (38).

To date, no trials have addressed this question in IGRA positive and IGRA negative individuals. A recent systematic review found that the risk of disease in IGRA positive close contacts was similar to the rate of disease in close contacts who are TST positive (66). IT was also found that the relative risk of disease in IGRA positive compared to IGRA negative was similar to the relative risk of disease in TST positive vs. TST negative. From this one can infer that benefit of INH will be found only in those who are initially IGRA positive. However, this extrapolation needs to be confirmed by evidence from studies specifically addressing this issue.

In summary, LTBI treatment is beneficial only in patients with a positive test for LTBI. It is important to remember that these studies were all conducted in settings with high TB incidence, and therefore presumed high levels of TB exposure and transmission. In addition, all study populations were HIV infected and most had no access to anti-retroviral therapy. Hence we can assume they were very likely to have been immune suppressed. Therefore, these results should be considered highly relevant in low and middle income countries-TST negative persons should be given LTBI treatment only in exceptional circumstances. The one exception is in the situation of recent exposure. Following TB exposure and primary infection cell-mediated immunity will develop only after several weeks. In close contacts who are initially TST negative it is recommended that a second TST should be performed eight weeks after the end of exposure. By this time all tuberculin conversions would have occurred (67). In individuals at very high risk of rapidly developing active disease, such as very young children (under 5), or HIV infected it is prudent to give INH while awaiting the results of the second TST.

Conclusion: Why is there a debate about treating LTBI?

Despite clear evidence of benefits of LTBI therapy in persons with a positive TST and increased risk of reactivation, treatment of LTBI remains controversial. The reasons for the controversy may be the history of repeated cycles of enthusiastic recommendations of new regimens, followed by imprudent application of therapy, followed by disastrous adverse events (INH in 1971 and 2RZ in 2000). The controversy is further fuelled by studies documenting poor performance of programmes, leading many to conclude that the therapy is sub-optimal, rather than concluding that the programmes were suboptimal. Apparently contradictory risk-benefit studies, demonstrating marginal benefits in low risk persons, have added to the confusion.

As summarized (Table V) there are many parallels between treatment of LTBI and treatment of hypertension. Hypertension is also an asymptomatic condition with serious complications that can cause substantial morbidity and mortality, yet these can be successfully prevented with medication. In contrast to LTBI treatment, these medications must be taken for many years, and many are quite expensive. Treatment of hypertension is also associated with unpleasant side effects. Yet there is little or no debate about the value of treatment of hypertension.

Why then debate about treatment of LTBI?

Received December 24, 2010

References

(1.) World Health Organization. Global tuberculosis control. Surveillance, planning, financing: 2010. (Report No.: WHO/ HTM/TB/2006.362). Geneva: World Health Organization; 2010.

(2.) Rieder HL. Epidemiologic basis of tuberculosis control. 1st ed. Paris, France; International Union Against Tuberculosis and Lung Disease; 1999. p 1-162.

(3.) Enarson DA, Rieder HL, Arnadottir T, Trebucq A. Tuberculosis guide for low income countries. 5th ed. Paris: International Union Against Tuberculosis and Lung Disease; 2000.

(4.) Rieder HL. Interventions for tuberculosis control and elimination. Paris international Union Against Tuberculosis and Lung Disease; 2002.

(5.) Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. Adv Tuberc Res 1969; 17 : 28-106.

(6.) Sumartojo E. When tuberculosis treatment fails: a social behavioural account of patient adherence. Am Rev Resp Dis 1993; 147 : 1311-20.

(7.) Dosanjh DPS, Hinks T, Innes JA, Deeks JJ, Pasvol G, Hackforth S, et al. Improved diagnostic evaluation of suspected tuberculosis in routine practice. Ann Int Med 2008; 148 : 325-33.

(8.) Dash LA, Comstock GW, Flynn JPG. Isoniazid preventive therapy. Am Rev Respir Dis 1980;121 :1039-44.

(9.) Miller B, Snider DE. Physician noncompliance with tuberculosis preventive measures. Am Rev Resp Dis 1987; 135 : 1-2.

(10.) Sorresso D, Mehta JB, Harvill LM, Bentley S. Underutilization of isoniazid chemoprophylaxis in tuberculosis contacts 50 years of age and older: a prospective study. Chest 1995; 108 : 706-11.

(11.) Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; 2 : CD001363.

(12.) International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health org 1982; 60 : 555-64.

(13.) American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161 : S221-47.

(14.) Long RL, Ellis E. Canadian tuberculosis standards, 6th ed. Toronto: Canadian Lung Association, Public Health Agency of Canada, Tuberculosis Prevention and Control; 2007.

(15.) Snider DE Jr., Caras GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA 1986; 255 : 1579-83.

(16.) Dasgupta K, Schwartzman K, Marchand R, Tannenbaum TN, Brassard P, Menzies D. Comparison of cost effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med 2000; 162 : 2079-86.

(17.) Comstock GM. How much isoniazid is needed for prevention of tuberculosis in immunocompetent adults. Int J Tuberc Lung Dis 1999; 3 : 847-50.

(18.) LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis Infection in a Public Health Clinic. Am J Respir Crit Care Med 2003; 168 : 443-7.

(19.) Jasmer RM, Snyder DC, Chin DP, Hopewell PC, Cuthbert SS, Paz EA, et al. Twelve months of isoniazid compared with four months of Isoniazid and Rifampin for persons with radiographic evidence of previous tuberculosis. Am J Respir Crit Care Med 2000; 162 : 1648-52.

(20.) Dutt AK, Stead WW. Tuberculosis in the elderly. In: Bass JB, editor. The medical clinics in North America. Montreal: WB Saunders and CO.; 1993. p. 1353-68.

(21.) American Thoracic Society, Center for Disease Control. Preventive treatment of Tuberculosis. A joint statement of the Amercian Thoracic Society, National Tuberculosis and Respiratory Disease Association, and the Centre for Disease Control. Am Rev Respir Dis 1971; 104 : 460-3.

(22.) Garibaldi RA, Drustin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis. Am Rev Respir Dis 1972; 106 : 357-65.

(23.) Kopanoff DE, Snider D, Caras GJ. Isoniazid-related hepatitis. Am Rev Respir Dis 1978; 117 : 991-1001.

(24.) Snider D, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145 : 494-7.

(25.) Salpeter SR. Fatal Isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993; 159 : 560-4.

(26.) Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventative therapy of tuberculosis with Rifampin and Pyrazinamide. Am Rev Respir Dis 1989; 140 : 1189-93.

(27.) Gao XF, Wang L, Liu GJ, Wen J, Sun X, Xie Y, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis 2006; 10 : 1080-90.

(28.) Center for Disease Control. Fatal and Severe Hepatitis Associated with Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection--New York and Georgia, 2000. Morb Mortal Wkly Rep 2001; 50 : 289-91.

(29.) American Thoracic Society, Centres for Disease Control. Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in the American Thoracic Society/ CDC recommendations. MMWR 2001; 50 : 733-5.

(30.) Hong Kong Chest Service Tuberculosis Research Centre MBMRC. A Double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145 : 36-41.

(31.) Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166 : 1863-70.

(32.) Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130 : 1712.

(33.) Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170 : 445-9.

(34.) Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al-Jahdali H, et al. Adverse events with 4 months rifampin or 9 months isoniazid as therapy for latent TB infection: results of a randomized trial. Ann Intern Med 2008; 149 : 689-97.

(35.) Omerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998; 78 : 169-71.

(36.) Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005; 40 : 670-6.

(37.) Kunst H, Khan KS. Age-related risk of hepatotoxicity in treatment of latent tuberculosis infection ; a systematic review. Int J Tuberc Lung Dis 2010; 14 : 1374-81.

(38.) Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. A Randomized, Placebo- Controlled Trial of 6 versus 36 Months Isonizid tuberculosis Preventive Therapy for HIV-infected Adults in Botswana. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco 2010, poster #104LB 2010 February 18.

(39.) Nolan CM, Aitken ML, Elarth AM, Anderson KM, Miller WT. Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. Am Rev Respir Dis 1986; 133 : 431-6.

(40.) Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventative therapy with Pyrazinamide and Ofloxacin. Clin Infect Dis 1997; 24 : 1264-5.

(41.) Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005; 26 : 462-4.

(42.) Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatic N, Bozeman L, et al. Substitution of Moxifloxacin for Isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180 : 273-80.

(43.) Adhikari N, Menzies R. Community-based tuberculin screening in Montreal: A cost-outcome description. Am J Public Health 1995; 85 : 786-90.

(44.) Rose DN, Schechter CB, Silver AL. The age threshold for isoniazid chemoprophylaxis: a decision analysis for low risk tuberculin reactors. JAMA 1986; 256 : 2709-13.

(45.) Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for tuberculin reactor:take it or leave it. Am Rev Resp Dis 1988; 137 : 215-20.

(46.) Colice GL. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors. Arch Intern Med 1990; 150 : 2517-22.

(47.) Jordan TJ, Lewit EM, Reichman LB. Isoniazid preventive therapy for tuberculosis. Decision analysis considering ethnicity and gender. Am Rev Respir Dis 1991; 144 : 1118-9.

(48.) Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored Isoniazid Prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997; 127 : 1051-61.

(49.) Jordan TJ, Lewit EM, Montgomery RL, Reichman LB. Isoniazid as preventive in HIV-infected intravenous drug abusers. A decision analysis. JAMA 1991; 265 : 2987-91.

(50.) Rose DN. Short-course prophylaxis against tuberculosis in HIV-infected persons- a decisions and cost-effectiveness analysis. Ann Intern Med 1998; 129 : 779-86.

(51.) Menzies D, Gardiner G, Farhat M, Greenway C, Pai M. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis 2008; 12 : 498-505.

(52.) BC Center for Disease Control. Annual Report Tuberculosis Control in 2002. Vancouver, BC Ministry of Health; 2003.

(53.) Blum RN, Polish LB, Tapy JM, Catlin BJ, Cohn DL. Results of screening for tuberculosis in foreign-born persons applying for adjustment of immigration status. Chest 1993; 103 : 1670-4.

(54.) Yuan L, Richardson E, Kendall PRW. Evaluation of a tuberculosis screening program for high-risk students in Toronto schools. CMAJ 1995; 153 : 925-32.

(55.) Onofre Moran-Mendoza A. The value of the tuberculin skin test size in predicting the development of tuberculosis in contacts of active cases Department of Health Care and Epidemiology, University of British Columbia; 2004.

(56.) Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003; 7 : S384-90.

(57.) Aisu T, Raviglione MC, van Praag E, Eriki P, Narain JP, Barugahare L, et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. U S National Library of Medicine, National Institute of Health, 1995; March 9, p. 267-73.

(58.) World Health Organization. Guidelines for intensified tuberculosis case finding and isoniazid preventtive therapy for people living with HIV in resource constrained settings. Geneva : World Health Organization, 2011.

(59.) Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342 : 268-72.

(60.) Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337 : 801-8.

(61.) Hawken MP, Meme HK, Chakaya JM, Elliott LC, Morris JS, Githui, et al. Isoniazid preventive therapy for tuberculosis in HIV-infected adults: results of a randomized controlled trial. AIDS 1997; 11 : 875-82.

(62.) Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12 : 244757.

(63.) Gordin FM, Chaisson RE, Matts JP, Valdespino JL, Coberly J, Miller C, De lourdes Carcia M, et al. Rifampin and Pyrazinamide vs Isoniazid for prevention of tuberculosis in HIV-infected persons. JAMA 2000; 283 : 1445-50.

(64.) Garcia ML, Valdespino JL, Garcia-Sancho C, Weissenbacher M, Daniels E, Peruga A, et al. Compliance and side effects to chemoprophylaxis for TB in HIV+. Mexican experience. IX International Conference on AIDS, Abstract-Po-BO7-11. 1993.

(65.) Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. The Cochrane Library 1. 2010.

(66.) Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Mwansa J, Menzies D, et al. Predictive value of interferon release assays for incident active tuberculoasis: A systematic review. PLoS one in Press 2010.

(67.) Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999; 159 : 15-21.

(68.) Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174 : 935-52.

(69.) Menzies D, Adhikari N, Arieta M, Loo V. Efficacy of environmental measures in reducing potentially infectious bioaerosols during sputum induction. Infect Control Hosp Epidemiol 2003; 24 : 483-9.

(70.) Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137 : 640-7.

(71.) Haley CA, Stephan S, Vossel LF, Sherfy E.A., Laserson KF, Kainer MA. Successful use of rifampicin for Hispanic foreignborn patients with latent tuberculosis infection. Int J Tuberc LungDis 2008: 12 : 160-7.

Reprint requests: Dr Dick Menzies, 3650 St. Urbain Rm k1.24, Montreal, Quebec, H2X 2P4, Canada e-mail: dick.menzies@mcgill.ca

Dick Menzies, Hamdan Al Jahdali & Badriah Al Otaibi

Montreal Chest Institute, McGill University, Montreal, Quebec, Canada
Table I. Summary of LTBI regimens in common use

                      Efficacy
Regimen               (relative to placebo) (#)

INH: 6 months         69% (12)
INH: 9-12 months      90-93% (12,17)
RIF&PZA: 2 months     Equal to 6-12INH (27,63)
INH&RIF: 3-4 months   Equal to 6INH (30,36)
RIF: 3-4 months       65% (##) (30)

Regimen               Completion of therapy

INH: 6 months         50% (6,8,54)
INH: 9-12 months      <50% (31,33,34,69)
RIF&PZA: 2 months     6% > 6-12INH * (27)
INH&RIF: 3-4 months   6% > 6-12INH ** (36)
RIF: 3-4 months       22% > 9INH *** (31-34,71)

                      Serious adverse events

Regimen               Type                   Rate

INH: 6 months         Hepatitis              1-5% (23,68)
INH: 9-12 months      Hepatitis              1-5% (23,31,34,68)
RIF&PZA: 2 months     Hepatitis              3-5% (27,68,70)
INH&RIF: 3-4 months   Hepatitis ([dagger])   1-5% (36,37)
RIF: 3-4 months       Rash                   1-2% (31,34)
                      Hepatitis              <1% (31,32,34)

Superscript numerals denote reference nos.; INH, isoniazid, 6 INH,
6 months isoniazid; 6-12 INH, 6-12 months INH; PZA, Pyrazinamide;
RIF, Rifampins; "Efficacy from placebo randomized trials. If trials
were not placebo controlled then efficacy relative to INH is given;
(##) Based on one placebo-controlled trial with 3 months rifampin (30);
* Average 6% (range: -5 to 19%) better completion than with 6-12INH;
** Average 6% (range: 3 to 12%) better completion than with 6-12INH;
*** Average 22% (range: 18 to 27%) better completion than with 9INH;
([dagger]) Hepatitis more frequent with INH&RIF than INH alone (37);
Figures in parentheses denote Ref numbers

Table II. Risk benefit studies of INH for tuberculin reactors

                                                        Margin of
                             Age group    Preferred     benefit *
Study                 Year     (yr)      (INH or Not)    (days)

Low risk reactors

Rose et al (44)       1986     10-80         INH          1-16
Tsevat (45)           1988     20-80        No INH        4-17
Colice (46)           1990      30           INH          3-19
Jordan et al (47)     1991     20-35         INH          3-19
                                50          No INH        2-33
Salpeter et al (48)   1997     35-70         INH           3-5
High risk reactors
  (HIV infected)
Jordan et al (49)     1991     20-60         INH           285
Rose (50)             1998    Adults         INH           254

* Margin: means gain or loss of life expected with INH treatment,
relative to no treatment. Superscript numerals denote reference
numbers

Table III. True impact of large scale screening programmes

                   Total         TST      Medically   Started
                  screened     positive   evaluated     INH
Country         with TST (N)     (N)         (N)        (N)

Canada (52)        19,001       4,292                    814
USA (53)            4,840       2,039       1,528        853
Canada (54)           720         162         142         56
Canada (55)        33,146       7,668                  2,600
Canada (16) *       3,300       1,598         647        347
USA (56)           66,767      12,901                  9,018
Canada (45)         7,669         782         525        293
Uganda (57)         9,862        5227 *       579        520

                     Completed INH

                       Of all     Of all
                       positive   screened
Country          (N)    TST (%)      (%)

Canada (52)      452      11          2
USA (53)         716      35         15
Canada (54)       52      13          7
Canada (55)     1589      21          5
Canada (16) *    251      31         18
USA (56)        5746      37          9
Canada (45)      140      13          2
Uganda (57)      322       6          3

* In some studies the number of studies of TST positive is calculated
based upon the expected number of TST positive in the original
populations screened, because individuals did not accept TST or
did not return for reading. Superscript numerals denote reference
numbers

Table IV. Protection of INH against development of active TB in
HIV infected individuals who were TST positive or TST Negative
(from placebo controlled trials)

                                            Risk reduction compared
                                                  to placebo

                                            Among TST
                                             positive    Among TST
                                            persons %    negative
Studies                Year   Country         (range)     persons

Pape et al (59)        1993   Haiti         76 (0-94)    30 (0-85)
Whalen et al (60)      1997   Uganda        70 (32-87)   26 (0-70)
Hawken et al (61)      1997   Kenya         40 (0-77)     0 (0-45)
Mwinga et al (62)      1998   Zambia        72 (0-93)    18 (0-70)
Pooled (65)            2010   All           60 (35-76)   16 (0-40)
Samandari et al (38)   2009   Botswana **   90 (N/A)     14 (N/A)

* Pooled risk reduction from systematic review and meta-analysis
of the above 4 studies plus Gordin et al (63) and Garcia et al (64);
** The Botswana trial compared rate of reduction with 36 months INH
vs. 6 months INH in HIV infected persons who were initially TST
positive or TST negative, Hence the placebo control was given
from month 7 to 36; both groups received INH for the first 6
months. Superscript numerals denote reference numbers

Table V. Comparison of treatment of hypertension vs. treatment
of latent TB

Hypertension                      Latent TB infection

* Asymptomatic condition          * Asymptomatic condition
* Very serious complications      * Very serious complications
  --Death                           --Death,
  --Major disability                --Major disability
                                    --AND transmission
* Treatment is for years          * Treatment is max 9
                                    months
  --Expensive medications           --Cheap medications
  --Potential serious side          --Potential serious
    effects                           side effects
  --Requires close monitoring       --Requires close
    and follow up                     monitoring and
                                      follow up
* BUT--no debate about Treating   * WHY the debate about
                                  Treating??
COPYRIGHT 2011 Indian Council of Medical Research
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Menzies, Dick; Jahdali, Hamdan Al; Otaibi, Badriah Al
Publication:Indian Journal of Medical Research
Article Type:Report
Geographic Code:9INDI
Date:Mar 1, 2011
Words:6665
Previous Article:Towards personalized medicine--the role of methotrexate.
Next Article:Vitamin D deficiency in healthy breastfed term infants at 3 months & their mothers in India: seasonal variation & determinants.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters